Google
IMNM 株価分析 — Immunome Inc (Healthcare >> Biotechnology)
IMNM に関するよくある質問
IMNMのROE（自己資本利益率）は？
Immunome IncのROEは-38.15%です。
IMNMの配当利回りは？
Immunome Incの配当利回りは0.00%です。
IMNMの品質スコア（Quality Score）は？
当社のAIはIMNMの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
IMNMは今が買い時ですか？
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
IMNMはどのセクターに属しますか？
Immunome IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
IMNM AI Analysis Summary
Our AI summary for IMNM: Immunome Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -38.15%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 22.76
Price
-0.32
(-1.39%)
Day Change
|
|
|---|
IMNM, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 22.76 |
| PBV / Sector |
4.44 / 5.20
|
| Earning Per Share | -1.96 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
24.43 M
GREAT
|
| Average 1W Daily Value |
16.76 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:00 |
| Symbol | IMNM |
| Name | IMMUNOME INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 113.25 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,613.82 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 18702 North Creek Parkway, Bothell, WA, United States, 98011
Phone: 425 939 7410
Website: https://immunome.com
Employees: 206
Sector: Healthcare >> Biotechnology
Description: Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
